The Patent Finder
US

Pleuromutilin Derivatives for the Treatment of Diseases Mediated by Microbes

US 8,071,643 In force
OverviewFamilyAssignmentsSources & methods

Term ends Mar 25, 2033 · High confidence

Filed Sep 17, 2009 as application 12/531,839 · Granted Dec 6, 2011
Base term plus 303 days of patent term adjustment (USPTO delay)
Today
20 years from filing
2008 2033
Clock starts
Mar 19, 2008
Term ends
Mar 25, 2033
Granted
Dec 6, 2011
base term patent term adjustment fee events Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
303
Days of term adjustment
Read from the USPTO patent term adjustment record, not recalculated here.
None
Terminal disclaimer
No disclaimer on this record.
3 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
13
Family applications on record here
Applications sharing this one's continuity chain, as the file histories and patent records this site holds name them. The family may have others.

This patent's term runs 303 days past its 20-year base term on prosecution delay. All three maintenance fees are recorded paid; no more fees are due. Confidence: High. from the record

How we calculated this date

One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
StepInputDate after this stepConfidence
Base term, 20 years from filingClock starts Mar 19, 2008, when application PCT/AT2008/000097, the earliest non-provisional in its chain, was filed (this one was filed Sep 17, 2009)Mar 19, 2028High confidence
Continuity chainEvery parent in the chain resolvedno changeHigh confidence
Patent term adjustment+303 days, USPTO patent term adjustment recordJan 16, 2029High confidence
Terminal disclaimer capNone on recordno cap appliedHigh confidence
Patent term extension+1529 days, USPTO 35 U.S.C. 156 certificateadded to Jan 16, 2029: Mar 25, 2033High confidence
Fee events3 of 3 maintenance fees paidIn forceHigh confidence
Computed term endThe steps above, in orderMar 25, 2033High confidence

Partial family

Application PCT/AT2008/000097PCT application
no patent term
no patent term
US 8,071,643this patent
Mar 2033
Mar 2033
US 8,153,689In force
Mar 2028
Mar 2028
Application 13/438,160Abandoned
not computed
not computed
Application 14/283,734Abandoned
not computed
not computed
Application 15/480,756Abandoned
not computed
not computed
Application 16/023,880Abandoned
not computed
not computed
Application 16/277,143Abandoned
not computed
not computed
8 of 13 applications in this family shown, earliest filings first. Partial: 1 of the 13 has no file history here, so its row comes from the patent's own record or names the application alone. The family may have others.

Assignments

Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
RecordedAssignorAssigneeConveyance
Sep 17, 2009
Reel 23249, frame 229
Mang, Rosemarie; Heilmayer, Werner; Badegruber, Rudolf; Strickmann, Dirk B.; Novak, Rodger; Ferencic, Mathias; Bulusu, Atchyuta Rama Chandra MurtyNabriva Therapeutics AGAssignment of Assignor's Interest
Oct 13, 2014
Reel 33935, frame 48
Nabriva Therapeutics AGKreos Capital IV (UK) LimitedAssignment of Assignor's Interest
Sep 29, 2016
Reel 39894, frame 473
Kreos Capital IV (UK) LimitedNabriva Therapeutics AGRelease of Security Interest
Jul 18, 2018
Reel 47958, frame 106
Nabriva Therapeutics AGNabriva Therapeutics GmbHChange of Name
Dec 20, 2018
Reel 47973, frame 110
Nabriva Therapeutics GmbHHercules Capital, Inc.Intellectual Property Security Agreement
Jan 18, 2019
Reel 48062, frame 807
Nabriva Therapeutics GmbHHercules Capital, Inc.Security Interest
Mar 3, 2023
Reel 62881, frame 90
Hercules Capital, Inc.Nabriva Therapeutics GmbH; Zavante Therapeutics, Inc.Release of Security Interest
Mar 3, 2023
reel/frame not recorded
Hercules Capital, Inc.Nabriva Therapeutics GmbHRelease of Security Interest
Mar 3, 2023
reel/frame not recorded
Hercules Capital, Inc.Zavante Therapeutics, Inc.Release of Security Interest
Jun 20, 2023
Reel 64312, frame 350
Hercules Capital, Inc.Nabriva Therapeutics GmbHCorrective Assignment to Correct the Receiving Party Data and the Assignment Document Previously Recorded at Reel: 062881 Frame: 0090. Assignor(S) Hereby Confirms the Release of Security Interest.
Jan 9, 2025
Reel 69806, frame 458
Nabriva Therapeutics GmbHHong Kong King-Friend Industrial Company Ltd.Assignment of Assignor's Interest
Apr 3, 2025
Reel 70725, frame 291
Nabriva Therapeutics GmbHHong Kong King-Friend Industrial Company Ltd.Nunc Pro Tunc Assignment

Sources

Google Patents · The patent document at USPTO · Assignment records at USPTO

USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup

Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited